Showing 471-480 of 7650 results for "".
Cutaneous Superficial Leiomyosarcoma: A Treatment Conundrum
https://practicaldermatology.com/topics/general-topics/cutaneous-superficial-leiomyosarcoma-a-treatment-conundrum/21504/Select presentations given by dermatology residents at Cosmetic SurgeryDiagnosing Allergic Contact Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/diagnosing-allergic-contact-dermatitis/20460/Three cases of ACD reactions to over-the-counter antibiotic ointments.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeVtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.Dr. Battle on Skin of Color Update and Minimizing, Treating Complications from Energy-Based Devices
https://practicaldermatology.com/topics/skin-of-color/dr-battle-skin-color-update-and-minimizing-treating-complications-energy-based-devices/28655/Eliot Battle, MD, discusses the growth of Skin of Color Update, minimizing and treating complications when treating patients of skin of color, and integrating energy-based devices into your practice.PDT and Skin Cancer
https://practicaldermatology.com/series/pdt-in-practice/pdt-and-skin-cancer/20211/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, talks about how photodynamic therapy (PDT) has expanded treatment options for patients with skin cancers, and shares insights on how it can be integrated with care for patients with pre-cancerous abnormalities to prevent squamoRevealed: The Two Hottest New Skin Cancer Ingredients
https://practicaldermatology.com/conferences/scale-2023/revealed-the-two-hottest-new-skin-cancer-ingredients/20202/Todd Schlesinger, MD, discusses the growing role of exosomes and cannabidiol (CBD) in dermatology.Advances in Topicals for Skin Conditions
https://practicaldermatology.com/topics/psoriasis/advances-in-topicals-for-skin-conditions/20197/There are more topicals available today than ever before for acne, rosacea, and psoriasis, and even more are coming down the pike. Larry Green, MD, reviews the current topical landscape in dermatology and previews what’s in the pipeline.We Can Do Better
https://practicaldermatology.com/columns/clinical-focus-1/we-can-do-better/23901/Dermatologists must educate primary care physicians on prevention and screening.